Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results : (453) Arrow Down
Filter Results : (453) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (875)
    • Faculty Publications  (453)

    Show Results For

    • All HBS Web  (875)
      • Faculty Publications  (453)

      Pharmaceutical Industry Remove Pharmaceutical Industry →

      Page 1 of 453 Results →

      Are you looking for?

      → Search All HBS Web
      • April 18, 2022
      • Article

      Will mRNA Technology Companies Spawn Innovation Ecosystems?

      By: Christoph Grimpe, Timo Minssen, W. Nicholson Price, II and Ariel Dora Stern
      The mRNA technologies that helped rapidly create effective COVID-19 vaccines could become technology platform businesses, which has tremendous implications for players in the world of drug development. These platforms could attract other companies interested in...  View Details
      Keywords: Health Care; Digital Health; Technology; Innovation; Health Care and Treatment; Technological Innovation; Digital Transformation; Health Industry; United States
      Citation
      Register to Read
      Related
      Grimpe, Christoph, Timo Minssen, W. Nicholson Price, II, and Ariel Dora Stern. "Will mRNA Technology Companies Spawn Innovation Ecosystems?" Harvard Business Review (website) (April 18, 2022).
      • April 2022
      • Teaching Note

      CVS Health: Prescription for Transformation

      By: Rosabeth Moss Kanter and Catarina Martinez
      In 2021, new CEO Karen Lynch (named the most powerful woman in business) considered the next transformation phase for CVS Health (a Fortune 5 corporate giant). The 2018 acquisition of Aetna insurance brought her to the company as part of its long evolution from a...  View Details
      Keywords: Health; COVID-19 Pandemic; Primary Care; Leadership; Change Management; Women Executives; Retail; Pharmacy; Pharmacy Benefit Manager; Clinical Trials; Vaccination; Acquisition; Innovation and Invention; Transformation; Retail Industry; Retail Industry; Retail Industry; United States
      Citation
      Purchase
      Related
      Kanter, Rosabeth Moss, and Catarina Martinez. "CVS Health: Prescription for Transformation." Harvard Business School Teaching Note 322-122, April 2022.
      • March 2022
      • Teaching Note

      Digital Manufacturing at Amgen

      By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
      This teaching note provides guidance for instructors teaching “Digital Manufacturing at Amgen,” case no. 621-008.  View Details
      Keywords: Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information Technology; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Technology Adoption; Biotechnology Industry; Biotechnology Industry; United States; California; Puerto Rico; Rhode Island
      Citation
      Purchase
      Related
      Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Teaching Note 622-013, March 2022.
      • 2022
      • Book

      Les multinationales suisses dans l'arène politique (1942–1993) [Swiss Multinationals in the Political Arena (1942–1993)]

      By: Sabine Pitteloud
      En décembre 2020, les Suisses votaient sur l’initiative populaire « pour des multinationales responsables ». Cet épisode récent a rappelé que la régulation de l’activité des sociétés multinationales fait l’objet de luttes politiques, auxquelles participent les...  View Details
      Keywords: Multinational Enterprise; Multinational Companies; Multinational Corporations; Lobbying; Business & Government Relations; Labor Relations; Relocation; Offshoring And Outsourcing; Corporate Regulation; Transnational Regulation; Multinational Firms and Management; Business and Government Relations; Governing Rules, Regulations, and Reforms; International Relations; Food and Beverage Industry; Food and Beverage Industry; Food and Beverage Industry; Switzerland
      Citation
      Find at Harvard
      Purchase
      Related
      Pitteloud, Sabine. Les multinationales suisses dans l'arène politique (1942–1993) [Swiss Multinationals in the Political Arena (1942–1993)]. Genève, Suisse: Librairie Droz, 2022, French ed.
      • 2022
      • Working Paper

      How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?

      By: Leemore S. Dafny, Kate Ho and Edward Kong
      Drug copayment coupons to reduce patient cost-sharing have become nearly ubiquitous for high-priced brand-name prescription drugs. Medicare bans such coupons on the grounds that they are kickbacks that induce utilization, but they are commonly used by...  View Details
      Keywords: Prescription Drugs; Coupons; Impact; Health Care and Treatment; Markets; Price; Spending; Pharmaceutical Industry; United States
      Citation
      Find at Harvard
      Read Now
      Related
      Dafny, Leemore S., Kate Ho, and Edward Kong. "How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?" NBER Working Paper Series, No. 29735, February 2022.
      • 2022
      • Article

      Missing Novelty in Drug Development

      By: Joshua Krieger, Danielle Li and Dimitris Papanikolaou
      We provide evidence that risk aversion leads pharmaceutical firms to underinvest in radical innovation. We introduce a new measure of drug novelty based on chemical similarity and show that firms face a risk-reward trade-off: novel drug candidates are less likely to...  View Details
      Keywords: Drug Development; Risk Aversion; Research and Development; Innovation and Invention; Investment; Pharmaceutical Industry
      Citation
      SSRN
      Find at Harvard
      Register to Read
      Related
      Krieger, Joshua, Danielle Li, and Dimitris Papanikolaou. "Missing Novelty in Drug Development." Review of Financial Studies 35, no. 2 (February 2022): 636–679.
      • February 2022
      • Case

      Nuritas

      By: Mitchell Weiss, Satish Tadikonda, Vincent Marie Dessain and Emer Moloney
      Nora Khaldi had built a technology “to unlock the power of nature” in the service of extending human lifespan and improving health, and now in April 2020 was debating telling her Board of Directors she wanted to put on ice some of her discoveries. Nuritas, the company...  View Details
      Keywords: Cash Burn; Cash Flow Analysis; Pharmaceutical Companies; Founder; Artificial Intelligence; AI; Entrepreneurship; Health Testing and Trials; Health Care and Treatment; Decision Making; Market Entry and Exit; AI and Machine Learning; Pharmaceutical Industry
      Citation
      Educators
      Related
      Weiss, Mitchell, Satish Tadikonda, Vincent Marie Dessain, and Emer Moloney. "Nuritas." Harvard Business School Case 822-080, February 2022.
      • December 2021
      • Case

      Zoetis

      By: David E. Bell, Damien McLoughlin and Natalie Kindred
      Keywords: Strategy; Food; Change Management; Leadership; Diversity; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
      Citation
      Educators
      Purchase
      Related
      Bell, David E., Damien McLoughlin, and Natalie Kindred. "Zoetis." Harvard Business School Case 522-041, December 2021.
      • October 2021 (Revised March 2022)
      • Case

      The Opioid Settlement and Controversy Over CEO Pay at AmerisourceBergen

      By: Suraj Srinivasan and Li-Kuan Ni
      In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged had contributed to the nationwide...  View Details
      Keywords: Opioids; Drug; Investors; Shareholder Activism; Investment Activism; Executive Compensation; Corporate Accountability; Corporate Governance; Governance Compliance; Governance Controls; Risk Management; Corporate Social Responsibility and Impact; Business and Shareholder Relations; Business and Stakeholder Relations; Distribution Industry; Distribution Industry; Distribution Industry; United States; West Virginia; Tennessee; Ohio; Pennsylvania
      Citation
      Educators
      Purchase
      Related
      Srinivasan, Suraj, and Li-Kuan Ni. "The Opioid Settlement and Controversy Over CEO Pay at AmerisourceBergen." Harvard Business School Case 122-014, October 2021. (Revised March 2022.)
      • September 2021
      • Supplement

      Hester Pharmaceuticals (B): Securing Supply

      By: Dante Roscini and John Masko
      In 2020, amid the COVID-19 pandemic and a rise in “reshoring” sentiment in the U.S., Hester Pharmaceuticals had to decide whether to build a new plant for its new oncology drug Akrozumab in Germany or in the U.S., or whether it should hire a contract manufacturing...  View Details
      Keywords: COVID-19 Pandemic; Cost vs Benefits; Trade; Supply Chain; Global Strategy; Buildings and Facilities; Operations; Pharmaceutical Industry; Italy
      Citation
      Related
      Roscini, Dante, and John Masko. "Hester Pharmaceuticals (B): Securing Supply." Harvard Business School Supplement 722-009, September 2021.
      • Summer 2021
      • Article

      The Cost and Evolution of Quality at Cipla Ltd, 1935–2016

      By: Muhammad H. Zaman and Tarun Khanna
      This article examines the evolution of Indian pharmaceutical manufacturer Cipla towards producing drugs that met the quality standards of European and U.S. regulators. It employs new research in Cipla’s corporate archives, the Creating Emerging Markets database, and...  View Details
      Keywords: Cipla; Pharmaceuticals; Drug Quality; Generics; Quality; Standards; Information Technology; Cost; Organizational Culture; Business History; Pharmaceutical Industry; India
      Citation
      Find at Harvard
      Related
      Zaman, Muhammad H., and Tarun Khanna. "The Cost and Evolution of Quality at Cipla Ltd, 1935–2016." Business History Review 95, no. 2 (Summer 2021): 249–274.
      • 2021
      • Working Paper

      Accounting for Product Impact in the Pharmaceuticals Industry

      By: Amanda Rischbieth, George Serafeim and Katie Trinh
      We apply the product impact measurement framework of the Impact-Weighted Accounts Initiative (IWAI) in two competitor companies within the pharmaceuticals industry. We design a monetization methodology that allows us to calculate monetary impact estimates of accessible...  View Details
      Keywords: Product Innovation; Impact; Impact Investing; Impact Measurement; ESG; ESG (Environmental, Social, Governance) Performance; ESG Ratings; Social Corporate Responsibility; Corporate Social Responsibility; Social Impact; Pharmaceutical Companies; Pharmaceuticals; IWAI; Product Design; Product Positioning; Society; Environmental Sustainability; Corporate Social Responsibility and Impact; Product; Safety; Pharmaceutical Industry
      Citation
      SSRN
      Read Now
      Related
      Rischbieth, Amanda, George Serafeim, and Katie Trinh. "Accounting for Product Impact in the Pharmaceuticals Industry." Harvard Business School Working Paper, No. 21-139, June 2021.
      • 2021
      • Working Paper

      Regulatory Approval and Expanded Market Size

      By: Benjamin Berger, Amitabh Chandra and Craig Garthwaite
      Regulatory review of new medicines is often viewed as a hindrance to innovation by increasing the hurdle to bring products to market. However, a more complete accounting of regulation must also account for its potential market expanding effects through quality...  View Details
      Keywords: New Medicines; Regulatory Approval; Health Care and Treatment; Research and Development; Governing Rules, Regulations, and Reforms; Markets; Expansion; Pharmaceutical Industry
      Citation
      Find at Harvard
      Read Now
      Related
      Berger, Benjamin, Amitabh Chandra, and Craig Garthwaite. "Regulatory Approval and Expanded Market Size." NBER Working Paper Series, No. 28889, June 2021.
      • May 2021
      • Case

      The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease

      By: Amitabh Chandra, Spencer Lee-Rey and Caroline Marra
      This case explores incentives for rare disease drug development by chronicling the role of the Spinal Muscular Atrophy (SMA) Foundation in forming strategic partnerships with the scientific research community and pharmaceutical developers to transform the trajectory...  View Details
      Keywords: Innovation and Invention; Strategy; Business or Company Management; Society; Health; Public Administration Industry; Public Administration Industry; United States
      Citation
      Educators
      Purchase
      Related
      Chandra, Amitabh, Spencer Lee-Rey, and Caroline Marra. "The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease." Harvard Business School Case 621-112, May 2021.
      • May 2021
      • Article

      Private and Social Returns to R&D: Drug Development and Demographics

      By: Efraim Benmelech, Janice Eberly, Dimitris Papanikolaou and Joshua Krieger
      Investment in intangible capital such as R&D has increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer...  View Details
      Keywords: Drug Development; Research and Development; Investment Return; Demographics; Pharmaceutical Industry
      Citation
      Find at Harvard
      Register to Read
      Related
      Benmelech, Efraim, Janice Eberly, Dimitris Papanikolaou, and Joshua Krieger. "Private and Social Returns to R&D: Drug Development and Demographics." AEA Papers and Proceedings 111 (May 2021): 336–340.
      • 2021
      • Working Paper

      Which Markets (Don't) Drive Pharmaceutical Innovation? Evidence From U.S. Medicaid Expansions

      By: Craig Garthwaite, Rebecca Sachs and Ariel Dora Stern
      Pharmaceutical innovation policy involves managing a tradeoff between high prices for new products in the short-term and stronger incentives to develop products for the future. Prior research has documented a causal relationship between market size and pharmaceutical...  View Details
      Keywords: Pharmaceuticals; Medicaid; Innovation and Invention; Policy; Markets; Research and Development; Pharmaceutical Industry
      Citation
      Find at Harvard
      Read Now
      Related
      Garthwaite, Craig, Rebecca Sachs, and Ariel Dora Stern. "Which Markets (Don't) Drive Pharmaceutical Innovation? Evidence From U.S. Medicaid Expansions." NBER Working Paper Series, No. 28755, May 2021.
      • February 2021
      • Case

      Digital Manufacturing at Amgen

      By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
      This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is...  View Details
      Keywords: Digital Technologies; Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Information Technology; Technology Adoption; Biotechnology Industry; Biotechnology Industry; United States; California; Puerto Rico; Rhode Island
      Citation
      Educators
      Purchase
      Related
      Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Case 621-008, February 2021.
      • January 2021
      • Case

      Takeda Pharmaceutical Company Limited (A)

      By: David J. Collis, Nobuo Sato and Akiko Kanno
      This case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition would turn...  View Details
      Keywords: Pharmaceutical Companies; Pharmaceuticals; Biotech; Biotechnology; M&A; Mergers & Acquisitions; R&D; Talent Management; Mergers and Acquisitions; Globalization; Management; Global Strategy; Talent and Talent Management; Pharmaceutical Industry; Pharmaceutical Industry; Japan; Asia
      Citation
      Educators
      Purchase
      Related
      Collis, David J., Nobuo Sato, and Akiko Kanno. "Takeda Pharmaceutical Company Limited (A)." Harvard Business School Case 721-373, January 2021.
      • January 2021
      • Supplement

      Takeda Pharmaceutical Company Limited (B)

      By: David J. Collis, Nobuo Sato and Akiko Kanno
      This case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challenges Takeda and...  View Details
      Keywords: Pharmaceutical Companies; Pharmaceuticals; M&A; Mergers & Acquisitions; Biotech; Biotechnology; R&D; Talent Management; Mergers and Acquisitions; Globalization; Global Strategy; Talent and Talent Management; Strategy; Biotechnology Industry; Biotechnology Industry; Japan; Asia
      Citation
      Purchase
      Related
      Collis, David J., Nobuo Sato, and Akiko Kanno. "Takeda Pharmaceutical Company Limited (B)." Harvard Business School Supplement 721-374, January 2021.
      • January 2021 (Revised June 2021)
      • Case

      Hester Pharmaceuticals (A): A Pricing Dilemma

      By: Dante Roscini and John Masko
      In August 2019, the leadership of Hester Pharmaceuticals (Hester) had a problem. Italy promised to be a key market for their new breakthrough oncology drug Akrozumab, but for almost two years, its single-payer healthcare system had been unable to agree with Hester on a...  View Details
      Keywords: Macroeconomics; Trade; Price; Global Range; Global Strategy; Globalized Markets and Industries; Health Care and Treatment; Patents; Monopoly; Negotiation; Business and Government Relations; Risk and Uncertainty; Human Needs; Business Strategy; Commercialization; Pharmaceutical Industry; Italy
      Citation
      Educators
      Purchase
      Related
      Roscini, Dante, and John Masko. "Hester Pharmaceuticals (A): A Pricing Dilemma." Harvard Business School Case 721-001, January 2021. (Revised June 2021.)
      • 1
      • 2
      • …
      • 22
      • 23
      • →

      Are you looking for?

      → Search All HBS Web
      ǁ
      Campus Map
      Harvard Business School
      Soldiers Field
      Boston, MA 02163
      →Map & Directions
      →More Contact Information
      • Make a Gift
      • Site Map
      • Jobs
      • Harvard University
      • Trademarks
      • Policies
      • Accessibility
      • Digital Accessibility
      Copyright © President & Fellows of Harvard College